Recap: Raytheon Technologies Q4 Earnings

  Raytheon Technologies (NYSE:RTX) reported its Q4 earnings results on Tuesday, January 25, 2022 at 06:55 AM. Here's what investors need to know about the announcement.

 

Raytheon Technologies (NYSE:RTX) reported its Q4 earnings results on Tuesday, January 25, 2022 at 06:55 AM.

Here’s what investors need to know about the announcement.

Earnings

Raytheon Technologies beat estimated earnings by 5.88%, reporting an EPS of $1.08 versus an estimate of $1.02, which did not surprise analysts.

Revenue was up $625.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.18, which was followed by a 0.0% increase in the share price the next day.

Here’s a look at Raytheon Technologies’s past performance:

 

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate 1.08 0.93 0.88 0.70
EPS Actual 1.26 1.03 0.90 0.74
Revenue Estimate 16.36B 15.82B 15.36B 16.24B
Revenue Actual 16.21B 15.88B 15.25B 16.42B

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Raytheon Technologies management provided guidance for their next quarter, expecting earnings between $4.6 and $4.8 per share for the next quarter.

This represents a 335.19% in quarter-over-quarter growth for Raytheon Technologies, a bullish signal to many investors.

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

What’s Going On With Palantir Technologies Stock?

Palantir Technologies Inc (NYSE: PLTR) shares are trading higher by 8.11% to $8.86 going into the close of Thursday's session. Shares of companies in the broader software sector are trading higher following strong earnings from Meta, which has driven a rotation into tech and growth names.

PLTR

Read More

Neoleukin Therapeutics Announced Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at ASH 2021

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Expos

NLTX